229 - Risk of cataract surgery in subjects with heterozygous familial hypercholesterolemia in prolonged treatment with statins (ID 615)
- Victoria Marco Benedí, Spain
- Martín Laclaustra, Spain
- Juan M. Casado-Dominguez, Spain
- Rosa Villa Pobo, Spain
- Rocio Mateo-Gallego, Spain
- C Rosa M. Sánchez-Hernández, Spain
- Marta Blanco Nuez, Spain
- Emilio Ortega-Martínez de Victoria, Spain
- Marta Sitges, Spain
- Juan Pedro-Botet, Spain
- Jose Puzo, Spain
- Teresa Villarroel, Spain
- Fernando Civeira, Spain
Abstract
Background and Aims
To ascertain the prevalence of cataracts in elderly subjects with pathogenic mutation heterozygous familial hypercholesterolemia (HeFH) receiving lipid-lowering drugs: statins treatment ≥5 years with/without ezetimibe
Methods
This is an observational, multicentre, case-control study, with HeFH cases and controls from five lipid clinics in Spain. We collected data with the following inclusion criteria: a pathogenic mutation in a candidate gene for HeFH (LDLR, APOB, or PCSK9) in the subject or in a first-degree relative; historic LDLc levels ≥220 mg/dl without lipid-lowering therapy; and statin treatment ≥5 years. Controls were selected from relatives of HeFH patients from the lipid clinics, requiring the absence of hypercholesterolemia (LDLc <190 mg/dl without lipid-lowering treatment); age ≥55 years; and being HeFH partners who cohabited >25 years or HeFH siblings.
Results
We analyzed 205 subjects, 112 HeFH, and 93 controls, with mean age 71.8 (6.5) years and 70.0 (7.3) years, respectively. HeFH subjects presented no difference in clinical characteristics including smoking, hypertension and type 2 diabetes mellitus compared with controls (Table 1). The mean time of lipid-lowering treatment in HeFH was 22.5 (8.7) years. Cataract surgery rate was not significantly different between cases and controls. The presence of cataracts neither was associated with LDLc nor with the length of the statin therapy
Conclusions
In the present study, HeFH was not a risk factor for cataracts and prolonged statin treatment does not favor cataract development
